|
¡@¡@·|¡@¡@°T
Á`´Á¼Æ¡G²Ä496´Á2009¦~²Ä48´Á(98.12.18¡^µo¦æ ¡i¥»´Á·|°T¤U¸ü¡j
¬dÅçµn°O»Pªk³W¬ÛÃö°T®§
1.98¦~12¤ë23¤é¡]¬P´Á¤T¡^8:00-16:00¡F¥Ñ¤¤µØ¥Á°êÃÄ«~¦æ¾Pº[ºÞ²z¨ó·|¡]TPMMA¡^¥D¿ì¡A½Ã¥Í¸p¡B¤¤¥¡°·±d«OÀI§½«ü¾É¡A©ó¥x¤jÂå°|°ê»Ú·|ij¤¤¤ß401·|ij«Ç¡]¥x¥_¥«¤¤¥¿°Ï®}¦{¸ô2¸¹¡^Á|¿ì¡y2010¦~¤§ÃÄ·~®i±æ¡Ð·sÂåÀø¬Fµ¦¹ï²£·~ªº½ÄÀ»»P¹ïµ¦¡z¡A¶O¥Î2,000¤¸¡A12¤ë15¤é³ø¦WºI¤î¡C
2.98¦~12¤ë28¤é29¤é¡]¬P´Á¤@¡B¤G¡^8:30-16:30¡F¤¤µØµLµß»s¾¯¨ó·|©ó¥x¤j¾®ºA¬ì¾Ç¤¤¤ßº[ª«²z¾ÇÀ]ºtÁ¿ÆU¡]¥x¥_¥«Ã¹´µºÖ¸ô4¬q1¸¹¡Fªñ·s¥Í«n¸ô¡B·s¥è¸ô¤f¡^¥l¶}¡u¦p¦ó«Ø¥ßGMP«~½è¨t²Î¬ã°Q·|¡v¡C¶O¥Î¡G¸Ó·|·|û3,000¤¸¡A«D¸Ó·|·|û5,000¤¸¡C
ÂåÀø¬Fµ¦¬ÛÃö°T®§
1.98¦~12¤ë18¤é¡]¬P´Á¤¡^12:00-14:00¡F¤K¤j¨ó·|Áp®u·|©óTPADAÁ|¦æ¡C°Q½×ijÃD¡G1.°·«O§½¡uÃÄ«~¶O¥ÎÁ`ÃB¹ê¬I¤è®×(¯ó®×)¡v¤Î¦U¤½¨ó·|´£®×ª©¥»°Q½×¡C2.°·«Oªk¡uÃÄ«~¶O¥Î¤ä¥X¥Ø¼Ð¨î«×(¯ó®×)¡v×¥¿´£®×¤Î¦U¤½¨ó·|´£®×©Î×¥¿°Q½×¡C3.½T»{¤Wz¨â®×¤§´£®×»P¡yÃÄ«~¬Fµ¦¥þ°ê·|ij¡z¤K¤j¤½¨ó·|¤T¤jµ´¹ï¦@ÃѬO¬Û²Åªº¡C4.¤Wz¨â®×¤§´£®×action plan¡C
·|°È¬ÛÃö°T®§
1.98¦~12¤ë18¤é(¬P´Á¤)¤U¤È3¡G00~5¡G00¡F©ó¥»¤½·|¥l¶}²Ä¥|©¡²Ä¤Q¥|¦¸±`°È²zºÊ¨ÆÁp®u·|ij¡C
2.98¦~12¤ë17¤é(¬P´Á¥|)±ß¤W©ó¥x¥_°ê»«¶º©±Á|¦æÅw°e¤ý¤å¼w±`°Èºa°h±ß®b¡A¥»¤½·|²z¡BºÊ¨Æ¦h¤H°Ñ»P¡A®b·|¤¤²z¨Æªø¹{µo¼ú¬×¤ÎÃҮѥH·PÁ¤ý±`°È¬°ÃĬɤΤ½·|ºÉ¤ßºÉ¤O¡C
¡i°T®§Âા¡j
¤½·|¦¬¤å
¦æ¬F°|½Ã¥Í¸p
98.12.10½Ã¸pÃĦr²Ä0980036417¸¹¡@®Ñ¨ç ¥»¤½·|¦¬¤å607¸¹¡]12¤ë¡^
¥D¦®¡GGDH-PQQ¦å¿}¸Õ¯È¥i¯à¤zÂZ±wªÌ¦å¿}´ú¶q¡A³y¦¨¦å¿}ÀË´úÈ°¾°ª¡A¤×¨ä·í¬~µÇ±wªÌ·f°t¨Ï¥Î¬Y¨ÇªvÀøÃĪ«®É¡A¥i¯à¾ÉP¦å¿}¼ÆȧPÂ_¿ù»~¡AÄY«®É¥i¯à¾ÉP¯f±w©ü°g©Î¦º¤`µ¥¤£¨}¨Æ¥ó¡A½Ð¶Q·|Âા·|ûª`·N¡A½Ð¡@¬d·Ó¡C ¡°¤½¨ç¥þ¤å¤@¡B¥þ¤å¤G¤U¸ü¡C
¦æ¬F°|½Ã¥Í¸pÃĪ«¹«~ÀËÅ秽
98.12.16ÃÄÀË¥ø¦r²Ä098180050¸¹¡@¤½§i¡@¥»¤½·|¦¬¤å609¸¹(12¤ë)
¥D¦®¡G¤½§i¡u°]¹Îªk¤H¥x¥_¥«瑠¤½¹A·~²£¾P°òª÷·|¡Ð¹A·~ÀËÅ礤¤ß¡v¬°ÃĪ«¤Î¤ÆùÛ«~»{¥i¹êÅç«Ç¡A¨ä»{¥i½d³ò¡A¦pªþ¥ó¡C ¡°¤½¨ç¥þ¤å¤U¸ü¡C
¤¤¥¡°·±d«OÀI§½
98.12.14°·«O¼f¦r²Ä0980083131A¸¹¡@®Ñ¨ç¡@¥»¤½·|¦¬¤å608¸¹(12¤ë)
¥D¦®¡G¡u¥þ¥Á°·±d«OÀIÃÄ«~µ¹¥I³W©w¡Ð²Ä9³¹§ÜÀù½FÃĪ«Antineoplastics drugs 9.18.Trastuzumab(¦pHerceptin)¡v·~¸g¥»§½©ó¤¤µØ¥Á°ê¤E¤Q¤K¦~¤Q¤G¤ë¤Q¥|¤é¥H°·«O¼f¦r²Ä0980083131¸¹¥O×¥¿µo¥¬¡A¯÷ÀË°eµo¥¬¥O(§tªþ¥ó)1¥÷¡A½Ð¡@¬d·Ó¡C ¡°¤½¨ç¥þ¤å¤@¡B¥þ¤å¤G¤U¸ü¡C
98.12.15°·«O¼f¦r²Ä0980095858A¸¹¡@®Ñ¨ç¡@¥»¤½·|¦¬¤å610¸¹(12¤ë)
¥D¦®¡G¡u¥þ¥Á°·±d«OÀIÃÄ«~µ¹¥I³W©w¡Ð²Ä9³¹§ÜÀù½FÃĪ«Antineoplastics drugs 9.32.nilotinib(¦pTasigna)¡v·~¸g¥»§½©ó¤¤µØ¥Á°ê¤E¤Q¤K¦~¤Q¤G¤ë¤Q¤¤é¥H°·«O¼f¦r²Ä0980095858¸¹¥O×¥¿µo¥¬¡A¯÷ÀË°eµo¥¬¥O(§tªþ¥ó)1¥÷¡A½Ð¡@¬d·Ó¡C ¡°¤½¨ç¥þ¤å¤@¡B¥þ¤å¤G¤U¸ü¡C
¸gÀÙ³¡°ê»Ú¶T©ö§½
98.12.09¶T®i¦r²Ä09802508630¸¹¡@¨ç¡@¥»¤½·|¦¬¤å606¸¹(12)
¥D¦®¡G¬°§¹¾ã»`¶°°ê¤ºÁ|¿ì°ê»Ú·|ij¬ÛÃö¸ê°T¡AÚ§Q´£¤É§Ú°ê©ó°ê»Ú·|ij¨ó·|(International Congress ¡® Convention Association,ICCA)¤§°ê»Ú±Æ¦W¡A·q½Ð¡@¶Q³æ¦ì´£¨Ñ¥»(98)¦~¦Ü101¦~¥D¿ì©Î¤wÀò¡@¶Q³æ¦ì¸É§U¤§°ê»Ú·|ij¸ê°T¡A½Ð¡@¬d·Ó´f´_¡C ¡°ªþªí¤å¥ó¤U¸üºô§}¡Ghttp://tinyurl.com/ygwtdz7¡C |
| |